1365-2125/asset/olbannerleft.gif?v=1&s=e86b92cac3efbbd2e255b9fa97ece9623eac0b54)
1365-2125/asset/olbannerright.gif?v=1&s=6a7c47d290382bf3bc40c62461bc36a371a081bf)
Review
Gut hormones: the future of obesity treatment?
Article first published online: 13 NOV 2012
DOI: 10.1111/j.1365-2125.2012.04278.x
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society
Additional Information
How to Cite
McGavigan, A. K. and Murphy, K. G. (2012), Gut hormones: the future of obesity treatment?. British Journal of Clinical Pharmacology, 74: 911–919. doi: 10.1111/j.1365-2125.2012.04278.x
Publication History
- Issue published online: 13 NOV 2012
- Article first published online: 13 NOV 2012
- Accepted manuscript online: 27 MAR 2012 05:41AM EST
- Received; 10 November 2011; Accepted; 21 March 2012; Accepted Article Published Online; 27 March 2012
- Abstract
- Article
- References
- Cited By
Keywords:
- glucagon-like peptide-1;
- gut hormones;
- obesity;
- oxyntomodulin;
- pancreatic polypeptide;
- peptide YY
Obesity is a major worldwide health problem. The treatment options are severely limited. The development of novel anti-obesity drugs is fraught with efficacy and safety issues. Consequently, several investigational anti-obesity drugs have failed to gain marketing approval in recent years. Anorectic gut hormones offer a potentially safe and viable option for the treatment of obesity. The prospective utility of gut hormones has improved drastically in recent years with the development of longer acting analogues. Additionally, specific combinations of gut hormones have been demonstrated to have additive anorectic effects. This article reviews the current stage of anti-obesity drugs in development, focusing on gut hormone-based therapies.